{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:47:16Z","timestamp":1764510436901},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,7,3]],"date-time":"2012-07-03T00:00:00Z","timestamp":1341273600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1038\/leu.2012.178","type":"journal-article","created":{"date-parts":[[2012,7,3]],"date-time":"2012-07-03T06:36:40Z","timestamp":1341297400000},"page":"233-235","source":"Crossref","is-referenced-by-count":18,"title":["Pretreatment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicin"],"prefix":"10.1038","volume":"27","author":[{"given":"M","family":"Kurimoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Hanaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Uneda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Murayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Sonoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Nakakuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,7,3]]},"reference":[{"key":"BFleu2012178_CR1","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1002\/cncr.11791","volume":"98","author":"F Giles","year":"2003","unstructured":"Giles F, Estey E, O\u2019Brien S . Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer 2003; 98: 2095\u20132104.","journal-title":"Cancer"},{"key":"BFleu2012178_CR2","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1182\/blood.V97.10.3197","volume":"97","author":"VH van Der Velden","year":"2001","unstructured":"van Der Velden VH, te Marvelde JG, Hoogeveen PG, Bernstein ID, Houtsmuller AB, Berger MS et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 2001; 97: 3197\u20133204.","journal-title":"Blood"},{"key":"BFleu2012178_CR3","first-page":"1324","volume":"87","author":"G Leone","year":"2002","unstructured":"Leone G, Teofili L, Voso MT, Lubbert M . DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica 2002; 87: 1324\u20131341.","journal-title":"Haematologica"},{"key":"BFleu2012178_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00277-003-0798-7","volume":"83","author":"U Lehmann","year":"2004","unstructured":"Lehmann U, Brakensiek K, Kreipe H . Role of epigenetic changes in hematological malignancies. Ann Hematol 2004; 83: 137\u2013152.","journal-title":"Ann Hematol"},{"key":"BFleu2012178_CR5","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1182\/asheducation-2011.1.543","volume":"2011","author":"T Graubert","year":"2011","unstructured":"Graubert T, Walter MJ . Genetics of myelodysplastic syndromes: new insights. Hematology Am Soc Hematol Educ Program 2011; 2011: 543\u2013549.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"BFleu2012178_CR6","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1182\/blood.V100.8.2957","volume":"100","author":"M Daskalakis","year":"2002","unstructured":"Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Kohler G, Wijermans P et al. Demethylation of a hypermethylated P15\/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2\u2032-deoxycytidine (decitabine) treatment. Blood 2002; 100: 2957\u20132964.","journal-title":"Blood"},{"key":"BFleu2012178_CR7","doi-asserted-by":"publisher","first-page":"3938","DOI":"10.1158\/1078-0432.CCR-08-2783","volume":"15","author":"JP Issa","year":"2009","unstructured":"Issa JP, Kantarjian HM . Targeting DNA methylation. Clin Cancer Res 2009; 15: 3938\u20133946.","journal-title":"Clin Cancer Res"},{"key":"BFleu2012178_CR8","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1038\/sj.leu.2403390","volume":"18","author":"R Tang","year":"2004","unstructured":"Tang R, Faussat AM, Majdak P, Perrot JY, Chaoui D, Legrand O et al. Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1. Leukemia 2004; 18: 1246\u20131251.","journal-title":"Leukemia"},{"key":"BFleu2012178_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nm1160","volume":"11","author":"A Insinga","year":"2005","unstructured":"Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2005; 11: 71\u201376.","journal-title":"Nat Med"},{"key":"BFleu2012178_CR10","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/sj.leu.2404477","volume":"21","author":"B ten Cate","year":"2007","unstructured":"ten Cate B, Samplonius DF, Bijma T, de Leij LF, Helfrich W, Bremer E . The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells. Leukemia 2007; 21: 248\u2013252.","journal-title":"Leukemia"},{"key":"BFleu2012178_CR11","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1182\/blood-2003-02-0396","volume":"102","author":"RB Walter","year":"2003","unstructured":"Walter RB, Raden BW, Hong TC, Flowers DA, Bernstein ID, Linenberger ML . Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. Blood 2003; 102: 1466\u20131473.","journal-title":"Blood"},{"key":"BFleu2012178_CR12","doi-asserted-by":"crossref","unstructured":"Petersdorf S, Kopecky K, Stuart RK, Larson RA, Nevill TJ, Stenke L et al. Preliminary results of southwest oncology group study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. Blood 2009; 114, (ASH Abstract, 790).","DOI":"10.1182\/blood.V114.22.790.790"},{"key":"BFleu2012178_CR13","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","volume":"29","author":"AK Burnett","year":"2011","unstructured":"Burnett AK, Hills RK, Milligan D, Kjeldsen L, Kell J, Russell NH et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 2011; 29: 369\u2013377.","journal-title":"J Clin Oncol"},{"key":"BFleu2012178_CR14","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","volume":"379","author":"S Castaigne","year":"2012","unstructured":"Castaigne S, Pautas C, Terre C, Raffoux E, Bordessoule D, Bastie J-N . Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012; 379: 1508\u20131516.","journal-title":"Lancet"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/leu2012178.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2012178","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2012178.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T18:03:37Z","timestamp":1684433017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2012178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,3]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["BFleu2012178"],"URL":"https:\/\/doi.org\/10.1038\/leu.2012.178","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,3]]}}}